EUVIMEDEUVIMED entdecken
Open Access

Does Elevated High-Density Lipoprotein Cholesterol Protect Against Cardiovascular Disease?

Alexander C Razavi, Vardhmaan Jain, Gowtham R Grandhi, Parth Patel, Angelos Karagiannis, Nidhi Patel, Devinder S Dhindsa, Chang Liu iD, Shivang R Desai, Zakaria Almuwaqqat, Yan V Sun, Viola Vaccarino und 3 weitere

The Journal of Clinical Endocrinology & Metabolism · 2024

DOI: 10.1210/clinem/dgad406 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Alexander C Razavi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine, Atlanta, GA 30322, USA. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High-density lipoprotein (HDL) contributes to reverse cholesterol transport, which is 1 of the main explanations for the described inverse association between HDL-cholesterol (HDL-C) and atherosclerotic cardiovascular disease (ASCVD) risk. However, efforts to therapeutically raise HDL-C levels with niacin, fibrates, or cholesteryl ester transfer protein inhibitors have not demonstrated a reduction in ASCVD events when compared with placebo among individuals treated with statins. Furthermore, mendelian randomization studies suggest that HDL-C is unlikely to be a direct biologic variable impacting ASCVD risk. More recently, observations from well-conducted epidemiologic studies have indicated a nonlinear U-shaped relationship between HDL-C and subclinical atherosclerosis, and that very high HDL-C (≥80 mg/dL in men, ≥100 mg/dL in women) is paradoxically associated with higher all-cause and ASCVD-related mortality. These observations suggest that HDL-C is not a universal protective factor for atherosclerosis. Thus, there are several opportunities for reframing the contribution of HDL-C to ASCVD risk and related clinical calculators. Here, we examine our growing understanding of HDL-C and its role in ASCVD risk assessment, treatment, and prevention. We discuss the biological functions of HDL-C and its normative values in relation to demographics and lifestyle markers. We then summarize original studies that observed a protective association between HDL-C and ASCVD risk and more recent evidence indicating an elevated ASCVD risk at very high HDL-C levels. Through this process, we advance the discussion regarding the future role of HDL-C in ASCVD risk assessment and identify knowledge gaps pertaining to the precise role of HDL-C in atherosclerosis and clinical ASCVD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesHydroxymethylglutaryl-CoA Reductase InhibitorsAtherosclerosisMaleFemaleHumansCholesterol, HDLLipoproteins, HDLRisk Factors

Stichwörter der Autor:innen

HDL cholesterolapolipoprotein A-Icardiovascular diseaseslipidslipoproteinsrisk assessment

Substanzen

Cholesterol, HDLHydroxymethylglutaryl-CoA Reductase InhibitorsLipoproteins, HDL

Autor:innen und Institutionen

  • Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Virginia Commonwealth University Health Pauley Heart Center, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA.
  • Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA 30322, USA.

ORCID-Profile: Chang Liu, Laurence S Sperling, Anurag Mehta

Förderung

  • NIDDK NIH HHS
  • NHLBI NIH HHS
  • NIH

Zitieren

APA

Razavi, A. C., Jain, V., Grandhi, G. R., Patel, P., Karagiannis, A., Patel, N., Dhindsa, D. S., Liu, C., Desai, S. R., Almuwaqqat, Z., Sun, Y. V., Vaccarino, V., Quyyumi, A. A., Sperling, L. S., & Mehta, A. (2024). Does Elevated High-Density Lipoprotein Cholesterol Protect Against Cardiovascular Disease?. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad406

Vancouver

Razavi AC, Jain V, Grandhi GR, Patel P, Karagiannis A, Patel N, et al. Does Elevated High-Density Lipoprotein Cholesterol Protect Against Cardiovascular Disease?. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgad406

BibTeX
@article{Razavi2024,
  author = {Razavi, Alexander C and Jain, Vardhmaan and Grandhi, Gowtham R and Patel, Parth and Karagiannis, Angelos and Patel, Nidhi and Dhindsa, Devinder S and Liu, Chang and Desai, Shivang R and Almuwaqqat, Zakaria and Sun, Yan V and Vaccarino, Viola and Quyyumi, Arshed A and Sperling, Laurence S and Mehta, Anurag},
  title = {Does Elevated High-Density Lipoprotein Cholesterol Protect Against Cardiovascular Disease?},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  doi = {10.1210/clinem/dgad406}
}
Kostenlos starten →